AD-105 is under clinical development by Jiangsu Aidea Pharmaceutical and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AD-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AD-105 overview

AD-105 is under development for the treatment of excessive inflammatory response in hepatectomy in hepatocellular carcinoma.

Jiangsu Aidea Pharmaceutical overview

Jiangsu Aidea Pharmaceutical (Jiangsu Aidea) carries out the production and sales of human-derived protein products. The company offers formulated products which include folium senna granules, nitrendipine tablets, powered bacillus tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, among others. Its raw materials include human urinary kininogenase, high purity urokinase, and crude ulinastatin. The company is also involved in drug research and development, processing and sale of active ingredients of plant raw materials and animal organs. Jiangsu Aidea is headquartered in Yangzhou, Jiangsu, China.

For a complete picture of AD-105’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.